drugset / Trial / NCT01501708

Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection

NCT01501708 ↗

NaSingle-groupOpen-labelTreatment

Summary

In this prospective phase II observational study, we plan to assess the efficacy and tolerability of caspofungin based combined anti-fungal therapy for proven or probable IFI in a group of patients received allo-HSCT transplantation with high risk of IFI: HLA matched unrelated donor or mismatched donor conditioning with ATG containing regimen or present III-IV aGVHD or extensive GVHD undergoing high-dose steroid treatment.

Timeline

Start
2011-12
Primary completion
2017-06
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Amphotericin B Unknown 3 mg/kg —
Subject Caspofungin Other / unclassified 50 mg —
Subject Voriconazole Small molecule 4 mg/kg —
Background Fluconazole Small molecule — —
Background Itraconazole Small molecule — —